A González-Díaz1, J Càmara1, M Ercibengoa2, E Cercenado3, N Larrosa4, M D Quesada5, D Fontanals6, M Cubero1, J M Marimón2, J Yuste7, C Ardanuy8. 1. Microbiology Department, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Spain; Research Network for Respiratory Diseases (CIBERES), ISCIII, Madrid, Spain. 2. Research Network for Respiratory Diseases (CIBERES), ISCIII, Madrid, Spain; Biodonostia, Infectious Diseases Area, Respiratory Infection and Antimicrobial Resistance Group; Osakidetza Basque Health Service, Donostialdea Integrated Health Organization, Microbiology Department, San Sebastian, Spain. 3. Research Network for Respiratory Diseases (CIBERES), ISCIII, Madrid, Spain; Microbiology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain. 4. Microbiology Department, Hospital Universitari Vall d'Hebró, Barcelona, Spain. 5. Microbiology Dept. Clinical Laboratory North Metropolitan Area, Hospital Universitari Germans Trias i Pujol, UAB, Badalona, Spain. 6. Microbiology Department, Corporació Sanitària Parc Taulí, IU-UAB, Sabadell, Spain. 7. Research Network for Respiratory Diseases (CIBERES), ISCIII, Madrid, Spain; Pneumococcal Reference Laboratory, Centro Nacional de Microbiología, ISCIII, Madrid, Spain. 8. Microbiology Department, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Spain; Research Network for Respiratory Diseases (CIBERES), ISCIII, Madrid, Spain; Departament of Pathology and Experimental Therapeutics, University of Barcelona, Spain. Electronic address: c.ardanuy@bellvitgehospital.cat.
Abstract
OBJECTIVE: An early reduction of adult invasive pneumococcal disease (IPD) was observed after the 13-valent pneumococcal conjugate vaccine (PCV13) introduction for children in Spain. We analysed the epidemiology of adult IPD in the late-PCV13 period. METHODS: This was a prospective multicentre study of adult IPD involving six hospitals. Strains were serotyped, genotyped and studied for antimicrobial susceptibility. The late-PCV13 period was compared with the pre- and early-PCV13 periods. RESULTS: A total of 2197 episodes were collected-949 in 2008-2009, 609 in 2012-2013 and 639 in 2015-2016. The initial decrease of IPD observed (from 12.3/100 000 to 8.1/100 000; 2008-2009 versus 2012-2013) plateaued in 2015-2016 (8.3/100 000). IPD due to PCV13 serotypes decreased (from 7.7 to 3.5 to 2.3/100 000; p < 0.05), whereas IPD caused by non-PCV13 serotypes increased (from 4.5 to 4.6 to 6.0/100 000; p < 0.05). The most frequent serotypes in the late-PCV13 period were: 8 (15.1%), 3 (10.5%), 12F (7.9%) and 9N (5.4%). These serotypes were related to major genotypes: CC53 (59.8%) and CC404 (30.4%) for serotype 8, CC180 (64.1%) and CC260 (28.1%) for serotype 3, CC989 (91.7%) for serotype 12F and CC67 (84.8%) for serotype 9N. Penicillin-non-susceptibility (21.2%) was associated with serotypes 11A (CC156), 14 (CC156) and 19A (CC320), and macrolide-resistance was related to serotypes 24F and 19A. Rates of pneumococcal meningitis remained stable throughout the periods (ranges 0.9, 0.8 and 1.0/100 000). CONCLUSIONS: The initial decrease of adult IPD observed after PCV13 introduction for children has been balanced by the rise of non-PCV13 serotypes. The spread of antibiotic-resistant lineages related to non-PCV13 serotypes (11A and 24F) could be a threat for the treatment of serious pneumococcal diseases.
OBJECTIVE: An early reduction of adult invasive pneumococcal disease (IPD) was observed after the 13-valent pneumococcal conjugate vaccine (PCV13) introduction for children in Spain. We analysed the epidemiology of adult IPD in the late-PCV13 period. METHODS: This was a prospective multicentre study of adult IPD involving six hospitals. Strains were serotyped, genotyped and studied for antimicrobial susceptibility. The late-PCV13 period was compared with the pre- and early-PCV13 periods. RESULTS: A total of 2197 episodes were collected-949 in 2008-2009, 609 in 2012-2013 and 639 in 2015-2016. The initial decrease of IPD observed (from 12.3/100 000 to 8.1/100 000; 2008-2009 versus 2012-2013) plateaued in 2015-2016 (8.3/100 000). IPD due to PCV13 serotypes decreased (from 7.7 to 3.5 to 2.3/100 000; p < 0.05), whereas IPD caused by non-PCV13 serotypes increased (from 4.5 to 4.6 to 6.0/100 000; p < 0.05). The most frequent serotypes in the late-PCV13 period were: 8 (15.1%), 3 (10.5%), 12F (7.9%) and 9N (5.4%). These serotypes were related to major genotypes: CC53 (59.8%) and CC404 (30.4%) for serotype 8, CC180 (64.1%) and CC260 (28.1%) for serotype 3, CC989 (91.7%) for serotype 12F and CC67 (84.8%) for serotype 9N. Penicillin-non-susceptibility (21.2%) was associated with serotypes 11A (CC156), 14 (CC156) and 19A (CC320), and macrolide-resistance was related to serotypes 24F and 19A. Rates of pneumococcal meningitis remained stable throughout the periods (ranges 0.9, 0.8 and 1.0/100 000). CONCLUSIONS: The initial decrease of adult IPD observed after PCV13 introduction for children has been balanced by the rise of non-PCV13 serotypes. The spread of antibiotic-resistant lineages related to non-PCV13 serotypes (11A and 24F) could be a threat for the treatment of serious pneumococcal diseases.
Authors: Germaine Hanquet; Pavla Krizova; Tina Dalby; Shamez N Ladhani; J Pekka Nuorti; Kostas Danis; Jolita Mereckiene; Mirjam J Knol; Brita A Winje; Pilar Ciruela; Sara de Miguel; Maria Eugenia Portillo; Laura MacDonald; Eva Morfeldt; Jana Kozakova; Palle Valentiner-Branth; Norman K Fry; Hanna Rinta-Kokko; Emmanuelle Varon; Mary Corcoran; Arie van der Ende; Didrik F Vestrheim; Carmen Munoz-Almagro; Juan-Carlos Sanz; Jesus Castilla; Andrew Smith; Birgitta Henriques-Normark; Edoardo Colzani; Lucia Pastore-Celentano; Camelia Savulescu Journal: Emerg Infect Dis Date: 2022-01 Impact factor: 6.883
Authors: Stephanie W Lo; Kate Mellor; Robert Cohen; Alba Redin Alonso; Sophie Belman; Narender Kumar; Paulina A Hawkins; Rebecca A Gladstone; Anne von Gottberg; Balaji Veeraraghavan; K L Ravikumar; Rama Kandasamy; Sir Andrew J Pollard; Samir K Saha; Godfrey Bigogo; Martin Antonio; Brenda Kwambana-Adams; Shaper Mirza; Sadia Shakoor; Imran Nisar; Jennifer E Cornick; Deborah Lehmann; Rebecca L Ford; Betuel Sigauque; Paul Turner; Jennifer Moïsi; Stephen K Obaro; Ron Dagan; Idrissa Diawara; Anna Skoczyńska; Hui Wang; Philip E Carter; Keith P Klugman; Gail Rodgers; Robert F Breiman; Lesley McGee; Stephen D Bentley; Carmen Muñoz-Almagro; Emmanuelle Varon Journal: Lancet Microbe Date: 2022-08-16
Authors: Aida González-Díaz; Miguel P Machado; Jordi Càmara; José Yuste; Emmanuelle Varon; Miriam Domenech; María Del Grosso; José María Marimón; Emilia Cercenado; Nieves Larrosa; María Dolores Quesada; Dionisia Fontanals; Assiya El-Mniai; Meritxell Cubero; João A Carriço; Sara Martí; Mario Ramirez; Carmen Ardanuy Journal: Euro Surveill Date: 2020-04